LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

New York, New York-- (Newsfile Corp. - February 5, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk (NYSE: NVO) is under pressure from investors for more information about its ...

Mexico's President Claudia Sheinbaum said on Sunday that reason should prevail a day after her government and the U.S. announced tariffs against one another, raising her fist in the air as she ...

Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data ...

The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December. The experimental CagriSema shot ...